image credit- shutterstock
South Korea-based Lunit and US-based Agilent Technologies Inc. have announced a non-exclusive collaboration to develop artificial intelligence (AI)-based companion diagnostic solutions.
The collaboration will leverage Lunit’s AI technology and Agilent’s expertise in tissue-based companion diagnostics to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development.
Under this agreement, Lunit and Agilent will develop advanced AI-powered companion diagnostic tools designed to enhance the accuracy of diagnosis and the measurement of therapeutic efficacy. The initial focus will be on leveraging Lunit's AI algorithms with Agilent’s state-of-the-art assays to evaluate biomarkers critical for the development of new pharmaceutical therapies.
The joint solutions will support pharmaceutical companies in companion diagnostic (CDx) product development, improving the precision and accuracy of biomarker testing, and ultimately benefiting patients with more tailored treatment options.
The collaboration will initially focus on the co-development of AI-powered assays for use in research and clinical trials. This agreement marks a significant step forward for both companies as they seek to redefine the role of artificial intelligence in precision oncology and translational medicine.
